|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017725,
umls-concept:C0017890,
umls-concept:C0166415,
umls-concept:C0205314,
umls-concept:C0220781,
umls-concept:C0243192,
umls-concept:C0441655,
umls-concept:C0679622,
umls-concept:C1552644,
umls-concept:C1554184,
umls-concept:C1568490,
umls-concept:C1568491,
umls-concept:C1611588,
umls-concept:C1707689,
umls-concept:C1823153,
umls-concept:C1883254,
umls-concept:C2349976
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-3-17
|
|
pubmed:abstractText |
Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPARalpha (EC(50) = 320 nM) and PPARgamma(EC(50) = 110 nM). Compound 2 shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. Compound 2 is currently in clinical development for the treatment of type 2 diabetes and dyslipidemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:BillerScott ASA,
pubmed-author:CapMichaelM,
pubmed-author:ChandrasenaGaminiG,
pubmed-author:ChangShu YSY,
pubmed-author:ChenSeanS,
pubmed-author:ChengLinL,
pubmed-author:ChengPeter T WPT,
pubmed-author:DevasthalePratik VPV,
pubmed-author:DoweykoArthurA,
pubmed-author:FarrellyDennisD,
pubmed-author:GollaRajasreeR,
pubmed-author:GroverGaryG,
pubmed-author:HariharanNarayananN,
pubmed-author:HarrityThomasT,
pubmed-author:HumphreysW GriffithWG,
pubmed-author:JeonYoonY,
pubmed-author:LeeJisunJ,
pubmed-author:MaZhengpingZ,
pubmed-author:MooreLisaL,
pubmed-author:QuFuchengF,
pubmed-author:RyonoDenis EDE,
pubmed-author:SassevilleVito GVG,
pubmed-author:SeethalaRamakrishnaR,
pubmed-author:SelanFredF,
pubmed-author:ShaoChunningC,
pubmed-author:SlephPaulP,
pubmed-author:SunWeiW,
pubmed-author:TiemanAaronA,
pubmed-author:VighB JBJ,
pubmed-author:WetterauJohn RJR,
pubmed-author:ZhangHaoH
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
24
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2248-50
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15771468-Adipocytes,
pubmed-meshheading:15771468-Animals,
pubmed-meshheading:15771468-Blood Glucose,
pubmed-meshheading:15771468-Cell Line,
pubmed-meshheading:15771468-Diabetes Mellitus, Type 2,
pubmed-meshheading:15771468-Fatty Acids,
pubmed-meshheading:15771468-Glycine,
pubmed-meshheading:15771468-Humans,
pubmed-meshheading:15771468-Hyperlipidemias,
pubmed-meshheading:15771468-Hypoglycemic Agents,
pubmed-meshheading:15771468-Hypolipidemic Agents,
pubmed-meshheading:15771468-Insulin,
pubmed-meshheading:15771468-Male,
pubmed-meshheading:15771468-Mice,
pubmed-meshheading:15771468-Mice, Obese,
pubmed-meshheading:15771468-Oxazoles,
pubmed-meshheading:15771468-PPAR alpha,
pubmed-meshheading:15771468-PPAR gamma,
pubmed-meshheading:15771468-Transcriptional Activation,
pubmed-meshheading:15771468-Triglycerides
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
|
|
pubmed:affiliation |
Metabolic Diseases Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-5400, USA. pratik.devasthale@bms.com
|
|
pubmed:publicationType |
Journal Article
|
